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SUMMARY
Background
Polymorphisms in the IL-28B region are a strong predictor of sustained
virologic response (SVR) in individual studies of HCV genotype 1 patients
receiving peginterferon (pegIFN) and ribavirin.
Aim
To obtain a pooled odds ratio (OR) of SVR in patients of varying race with
the favourable IL-28B genotype compared to those with the unfavourable
genotype.
Methods
A literature search was conducted using online databases and a review of
conference abstracts. A random effects meta-analysis was performed and
study heterogeneity and publication bias were assessed.
Results
There were 21 individual studies of HCV genotype 1 patients of varying
ethnicity treated with pegIFN and ribavirin. The pooled prevalence of the
favourable IL-28B genotype varied by race (73% vs. 41% vs. 13% in 2612
Asians, 3110 Caucasians and 452 African-Americans, respectively,
P < 0.001). However, the strength of association of the IL-28B genotype
with SVR was similar in all three racial groups (Caucasians: odds ratio
(OR) 3.88, 2.75–5.49, African-Americans: OR 4.63, 2.52–8.50 and Asians
OR 5.66, 3.99–8.02, all P < 0.001). The IL-28B genotype was also associated
with SVR in 263 HIV/HCV co-infected Caucasians (OR 5.49, 3.02–9.96,
P < 0.001). Study quality score and anti-viral treatment regimen did not
impact the strength of the association in patient subgroups nor in the
pooled population.
Conclusions
IL-28B genotype is signiﬁcantly associated with SVR in HCV genotype 1
patients of varying race, as well as in HIV co-infected patients, receiving
pegIFN and ribavirin. IL-28B testing in conjunction with other pre-treat-
ment parameters may prove useful in counselling HCV patients.
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INTRODUCTION
Long-term sequelae of untreated chronic hepatitis C
virus (HCV) infection include the development of pro-
gressive hepatic necroinﬂammation and ﬁbrosis which
can lead to life-threatening decompensated cirrhosis and
hepatocellular carcinoma (HCC).1 Nearly 50% of HCV
patients will achieve a sustained virologic response
(SVR) after treatment with peginterferon (pegIFN) and
ribavirin for 24–48 weeks that is associated with
improved long-term clinical outcomes including survival
compared with nonresponders.2–5 However, the majority
of HCV patients in western countries are infected with
HCV genotype 1, wherein the observed SVR rate is
lower (40%) after 48 weeks of full dose pegIFN and riba-
virin treatment.4
As interferon therapy is associated with frequent and
potentially serious side effects, it is important that clini-
cians be able to make accurate predictions regarding the
likelihood of an SVR for individual patients with HCV
genotype 1 infection. Clinical features associated with a
lower likelihood of achieving SVR can be grouped into
host, viral and treatment related factors.3–9 Host factors
associated with a poorer response include increasing
patient age, male gender, higher body mass index (BMI),
non-Caucasian race and greater degrees of hepatic stea-
tosis and ﬁbrosis on biopsy, whereas viral factors include
HCV genotype 1/4 and a higher baseline viral load. In
addition, the rate of decline in viral load at week 4 (i.e.
rapid virologic response or RVR) and week 12 (i.e. early
virologic response or EVR) provides additional prognos-
tic value.3, 6
A single nucleotide polymorphism (SNP) upstream of
the interleukin 28B (IL-28B) gene on chromosome 19
was recently shown to be strongly associated with SVR
in previously untreated HCV genotype 1 patients.7 The
identiﬁed polymorphism in this gene, which encodes for
interferon-k-3, is associated with hepatic responsiveness
to exogenously administered interferon as well as the
rate of hepatocyte death.8–10 In a cohort of treatment
naïve HCV genotype 1 patients, the IL-28B SNP,
rs12979860, was associated with a nearly two-fold higher
SVR rate among patients with the favourable CC geno-
type compared to those with the CT or TT genotypes.7
The IL-28B polymorphism may also explain at least half
of the difference in SVR rates observed in Caucasians
and African-Americans who received the same treatment
with comparable adherence.7, 11 Reliable estimates of the
effect of IL-28B polymorphisms on SVR are not known,
in part, due to the variable sample size and heterogeneity
of HCV patients and treatment regimens used in many
of the individual studies. Therefore, the current meta-
analysis was undertaken to better quantify the effect of
the IL-28B polymorphism on the likelihood of achieving
SVR in HCV genotype 1 patients. In addition, evaluation
of the impact of several host [i.e. subject race, human
immunodeﬁciency virus (HIV) co-infection] and treat-
ment factors (i.e. duration and dosing) on the utility of
IL-28B testing in predicting SVR was undertaken.
METHODS
Literature search
A MEDLINE computer database search of manuscripts
published between January 2000 and July 2011 was per-
formed using the text-words IL-28B, IL28 and interleu-
kin 28. A similar search was conducted using PUBMED
and EMBASE for articles published during the same time
period. Additional manual and electronic searches of
abstracts presented at the annual American Gastroenter-
ology Association from 2007 to 2011 and American
Association for the Study of Liver Diseases meetings
from 2007 to 2010 was undertaken. Finally, consultation
with expert hepatologists as well as manual recursive
searches of references from review articles and published
studies were completed to identify any additional
abstracts or unpublished data.
Study selection criteria
Studies were selected based on the following inclusion
criteria: (i) published studies of IL-28B genotyping in
adults with chronic HCV genotype 1 infection; (ii)
treatment with pegIFN and ribavirin and (iii) reported
outcome of SVR. The following exclusion criteria were
also used: (i) use of direct acting anti-viral agents
(DAAs); (ii) treatment of patients who had undergone
liver transplantation and (iii) use of IL-28B SNPs other
than rs12979860 or rs8099917. All published studies
regardless of the number of patients reported were
included. After reviewing the titles and abstracts of all
citations identiﬁed in the literature search, two investi-
gators (AS, RF) independently applied the selection cri-
teria and extracted data. Any disagreements were
resolved by consensus, and agreement between investi-
gators for selection of studies for this meta-analysis was
greater than 95%.
Data extraction
Eligible studies were reviewed in a duplicate but
independent manner by two investigators (AS, RF). For
each study, the investigators collected the following data:
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(i) Study: year, location, design, publication status; (ii)
Patient factors: total number and mean age, baseline
serum aspartate aminotransferase (AST), baseline alanine
aminotransferase, BMI and per cent with diabetes mell-
itus, male gender, treatment naïve and HIV co-infection;
(iii) HCV factors: HCV genotype, baseline HCV RNA
level, total number of patients achieving RVR and SVR;
(iv) Treatment factors: adherence to established HCV
treatment guidelines,12 duration of both pegIFN and
ribavirin, type of pegIFN used, dose reduction in anti-
viral medications, use of growth factors for cytopenias
and (v) IL-28B: IL-28B SNP tested and number of
patients with each IL-28B genotype and number with
each IL-28B genotype who achieved RVR and SVR. For
subgroup analyses, full-dose therapy was deﬁned as
either pegIFN a-2a 180 mcg or pegIFNa-2b  1.0 mcg/
kg/week in combination with ribavirin  800 mg daily.
Any discrepancies in data extraction were resolved by
discussion among the investigators.
IL-28B testing
The two IL-28B SNPs reported in the individual studies
were rs12979860 and rs8099917 which are in linkage dis-
equilibrium with each other. The favourable genotype for
rs12979860 is CC, whereas the unfavourable genotypes
are CT and TT. The favourable genotype for rs8099917
is TT, whereas the unfavourable genotypes are TG and
GG. Data from studies using both SNPs were initially
merged as they are highly concordant in almost all East
Asians and the majority of Caucasians. However, sepa-
rate sensitivity analyses were conducted after excluding
Caucasian studies using rs8099917 as the two SNPs do
not reliably provide comparable results in this popula-
tion.13 When individual studies reported data for both
SNPs, only the most robustly studied SNP for each race
was chosen (i.e. rs8099917 for Asians and rs12979860
for non-Asians).
Primary outcome
The primary outcome for this meta-analysis was achieve-
ment of SVR after pegIFN and ribavirin treatment,
which was deﬁned as undetectable serum HCV RNA by
polymerase chain reaction testing 24 weeks after treat-
ment.
Secondary outcome
A secondary outcome for this meta-analysis was achieve-
ment of RVR with pegIFN and ribavirin treatment. RVR
was deﬁned as an undetectable serum HCV RNA at
week 4 of treatment. An additional secondary outcome
included crude pooled rates of the IL-28B genotype by
race.
Quality assessment
A study quality assessment scale was created based on
previously validated tools designed for diagnostic accu-
racy studies.14–16 This eight-item scoring system involved
questions about sample purity (based on inclusion of
only treatment naïve and HCV genotype 1 patients),
reporting of other known pre-treatment host factors
associated with SVR and use of well-established HCV
treatment algorithms with validated stopping rules. A
score  6 was deﬁned as high quality and a score <6 as
low quality.
Statistical analysis
A pooled odds ratio (OR) of SVR based on the favour-
able IL-28B genotype was the estimate of effect, and was
determined using the DerSimonian and Laird method
for a random effects method. Study heterogeneity was
assessed by the I2 test, where an I2 >50% is suggestive of
substantial heterogeneity. Publication bias was assessed
using the Harbord and Peters tests. Inﬂuence analysis
was performed by removing one study at a time from
the model to see if there was undue inﬂuence by a single
study. All statistics were computed using STATA 11.0
(StataCorp LP, College Station, TX, USA).
The data from the included studies were analysed sep-
arately by patient race. In addition, because the recom-
mended dose of ribavirin is lower and the anticipated
SVR rate is also lower in HIV co-infected patients com-
pared with non-HIV patients, the HIV co-infection stud-
ies were analysed separately. Sensitivity and subgroup
analyses were performed based on IL-28B SNP, treat-
ment algorithm, treatment experience and overall study
quality score. Speciﬁc comparisons were made using
meta-regression.
RESULTS
Of the 180 published studies on IL-28B polymorphisms
in HCV patients, 130 were eliminated due to the lack of
reporting on virologic outcomes in treated patients.
Among the 50 remaining studies, two involved the use
of protease inhibitors with pegIFN and ribavirin, whereas
three included liver transplant recipients. Of the 25
studies of HCV genotype 1 patients, four were reported
in duplicate leaving a total of 21 analysable studies
(Figure 1). Studies published only as abstracts were not
included as they did not reliably provide extractable data
for SVR stratiﬁed by IL-28B genotype.
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Caucasians with HCV genotype 1
SVR outcome. There were nine studies of Caucasian
patients with HCV genotype 1 who did not have HIV
co-infection (Table 1).11, 17–24 All of the studies included
only HCV genotype 1 patients and six studies exclusively
enrolled treatment naïve patients. To maximise power,
the Alestig et al. study was included, which carries the
risk of overlapping some patients from the Lindh et al.
study.23, 24 However, Caucasian patients from the
McCarthy study were excluded from this analysis
because 25% of them had nongenotype 1 HCV infection.
The favourable IL-28B genotype (CC) was present in
41% of the 3110 pooled patients (Figure 2). Overall, 67%
of the CC genotype patients achieved SVR compared to
37% of those with the unfavourable IL-28B genotype
with a pooled OR of 3.88 (95% CI: 2.75–5.49, P < 0.001)
(Figure 3). The moderate to high heterogeneity among
these nine studies (I2 = 69%) was improved after remov-
ing the Suppiah study which was the only study to use
the rs8099917 SNP, with a similar pooled OR of 4.34
(95% CI: 3.27–5.24, P < 0.001), but a lower heterogene-
ity (I2 = 31%). A subgroup analysis involving the ﬁve
studies that used full dose pegIFN and ribavirin for
48 weeks vs. the four studies that did not led to a similar
result (OR 4.65 vs. 3.39, P = 0.45). Pooling of the six
high quality studies led to a pooled OR of 4.71 (95% CI:
3.37–6.57, P < 0.001). The six studies that only included
treatment naïve patients had a signiﬁcantly higher OR
for SVR compared with the three studies that included a
mixture of naïve and previously treated patients (4.71 vs.
2.44, P = 0.01).
RVR outcome. Data for the RVR outcome were available
in ﬁve of the nine Caucasian studies, and the favourable
IL-28B genotype (CC) was present in 35% of the 1861
pooled patients.11, 19–21, 24 The rate of RVR was 32% in
the CC patients compared to 8% in patients with the
unfavourable IL-28B genotype with a pooled OR of 5.29
(95% CI: 3.75–7.48, P < 0.001) (supplementary Figure
S1). Heterogeneity between studies was low (I2 = 26%).
The OR of SVR in these same ﬁve studies was 4.40 (95%
CI: 3.17–6.10, P < 0.001).
African-Americans with HCV genotype 1
SVR outcome. There were three studies of African-
American patients with HCV genotype 1 infection, and
they all utilised full dose pegIFN and ribavirin treatment
for 48 weeks (Table 1).11, 17, 25 These studies all reported
data for the rs12979860 SNP. The favourable IL-28B
genotype CC was present in only 13% of these 452
patients, which is signiﬁcantly lower than that seen in
the Caucasians and Asians (Figure 2). The SVR rate was
46% among CC patients compared to 19% among
patients with the unfavourable IL-28B genotype with a
pooled OR of 4.63 (95% CI: 2.52–8.50, P < 0.001) (Fig-
ure 3) and low study heterogeneity (I2 = 0%). Week 4
RVR data were only reported in one study.11
Asians with HCV genotype 1
SVR outcome. There were eight studies of Asian patients
with HCV genotype 1 treated with pegIFN and ribavirin
(Table 1).26–33 These studies all used the rs8099917 SNP
which is in strong linkage disequilibrium with rs12979860
in East Asians.13, 29 The 73% prevalence of the favourable
180
published
studies
50 studies
45 studies
25 studies
21 studies
2 studies of DAA
130 unrelated
studies
3 studies in liver
transplant
16 studies non-
HCV genotype 1
4 studies using
same study
populations
4 studies of
treatment
failures, acute
HCV infection,
or other IL28B
SNP
Figure 1 | Overview of study selection. There were 21
individual studies that met all of the inclusion and
exclusion criteria.
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IL-28B genotype (TT) among the 2612 patients was signif-
icantly higher than the prevalence in both the Caucasians
(P < 0.001) and African-Americans (P < 0.001) (Figure 2).
The pooled SVR rate was 58% in patients with the TT
genotype compared to only 20% in patients with the
unfavourable IL-28B genotype with a pooled OR of 5.66
Table 1 | Summary of the 21 individual studies included in the meta-analysis
Study N
Age
(mean)
Men
(%)
BMI
(kg/m2)
Advanced
ﬁbrosis (%)*
Treatment
duration
(weeks)
Prevalence
of favourable
IL-28B
genotype (%)
SVR in
favourable
IL-28B
genotype (%)
SVR in
unfavourable
IL-28B
genotype (%)
Caucasian (HIV)
Thompson (US) 1171 48 61 27 12 48 37 69 32
Darling (US) 111 48 65 n/a 19 48 49 91 63
Stattermayer
(Austria)
372 45 61 n/a 31 24–72 35 79 43
Bochud
(Europe/Israel)
170 41 70 25 35¶ 24–72 26 66 48
Montes-Cano
(Spain)
161 n/a 59 n/a 29 n/a† 39 54‡ 30‡
Fattovich (Italy) 121 46 64 25 22 48 35 83 38
Suppiah
(Australia/Europe)
848 43 62 26 n/a** 48 52 56‡ 36‡
Alestig (Sweden) 50 47 60 n/a 6†† 48 36 89 41
Lindh (Sweden) 106 45 61 n/a 23 24–72 36 79‡ 49‡
Total 3110 46 62% 20% 41% 67% 37%
African-American
(HIV)
Thompson (US) 300 51 57 29 10 48 14 48 14
McCarthy (US) 53 48 65 n/a 44 48 15 13§ 9§
Darling (US) 99 48 65 n/a 19 48 9 67 36
Total 452 50 60% 24% 13% 46% 19%
Asian (HIV)
Hayes (Japan) 812 58 56 23 75 48 72 53‡ 24‡
Kurosaki (Japan) 496 57 50 n/a 24  24 70 50‡ 13‡
Tanaka (Japan) 314 57 54 n/a 29 n/a 62 64§ 13§
Lin (Taiwan) 191 51 36 25 46 24 89 72 38
Sinn (Korea) 55 57 53 n/a 61 48 84 67§ 44§
Huang (Taiwan) 226 52 62 n/a n/a 24 83 65 26
Hayashi (Japan) 299 56 53 n/a 16 48 73 58‡ 14‡
Akuta (Japan) 219 54 63 23 n/a 48† 68 63‡ 26‡
Total 2612 56 54% 43% 73% 58% 20%
Caucasian (HIV+)
Aparicio (Spain) 86 48 67 n/a 39 n/a 60 50‡ 9‡
Pineda (Spain) 82 42 85 23 40 48 41 50 17
Rallon (Spain) 95 42 74 n/a n/a 48–72 36 65 30
Total 263 44 75% 39% 46% 54% 20%
BMI, body mass index; n/a, not available; SVR, sustained virologic response.
Demographic data may be from all patients in the study population, including some who did not undergo IL-28B genotyping.
* Not all patients in each study underwent liver biopsy. In most studies, advanced ﬁbrosis deﬁned as Ishak score 4, METAVIR
score  3.
† Some patients treated with either standard IFN + RBV or standard IFN alone.
‡ Study does not clearly state whether all patients were treatment naïve.
§ Some patients were not treatment naïve.
¶ Deﬁned advanced ﬁbrosis as Ishak score  2.
** Used Scheuer scoring system for liver ﬁbrosis.
†† Used Ludwig and Batts scoring system for liver ﬁbrosis.
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(95% CI: 3.99–8.02, P < 0.001) (Figure 3). There was
moderate heterogeneity among studies (I2 = 56%).
Removing the two studies that clearly included previously
treated nonresponders28, 30 resulted in a pooled OR of
SVR in the TT genotype of 5.06 (95% CI: 3.77–6.79,
P < 0.001) with lower heterogeneity (I2 = 32%). A sub-
group analysis of the six high quality compared to the two
low quality studies demonstrated similar OR (5.63 vs.
5.81, P = 0.98). Furthermore, the ﬁve studies that used full
dose pegIFN and ribavirin for 48 weeks had a similar OR
for SVR compared to the three studies that used alterna-
tive dosing and duration (6.14 vs. 4.87, P = 0.57).
RVR outcome. RVR data were reported in only two of
the Asian studies.27, 31 The favourable IL-28B genotype
(TT) was present in 74% of the 722 pooled patients. The
RVR rate was 25% in the TT patients as compared to
6% in the unfavourable IL-28B genotype patients, with a
pooled OR of 4.07 (95% CI: 2.13–7.75, P < 0.001) (sup-
plementary Figure S2).
HIV co-infected Caucasians with HCV genotype 1
SVR outcome. There were three studies of HIV (+) co-
infected Caucasian patients with HCV genotype 1 treated
with pegIFN and ribavirin (Table 1).34–36 The favourable
IL-28B genotype of CC was present in 46% of the 263
pooled patients, which was not signiﬁcantly different
from the Caucasian HCV patients without HIV co-infec-
tion (46% vs. 41%, P = 0.17) (Figure 2). Overall, 54% of
the HIV (+) patients with the CC genotype achieved
SVR compared to 20% of patients with the unfavourable
IL-28B genotype with a pooled OR of 5.49 (95% CI:
3.02–9.96, P < 0.001) (Figure 4) and there was low hetero-
geneity (I2 = 0%). However, none of these studies
reported week 4 viral kinetics.
Pooled analysis
As the impact of IL-28B genotype on SVR appeared sim-
ilar in all four of the analysed groups (Figures 3 and 4),
the data were pooled to increase the ability to determine
the impact of other study features. After combining all
21 studies with a total of 6437 patients, the pooled OR
of SVR for patients with the favourable IL-28B genotype
remained signiﬁcant at 4.68 (95% CI: 3.75–5.83,
P < 0.001). There was moderate heterogeneity between
studies (I2 = 58%), which was minimised with removal
of the Suppiah study (I2 = 30%). Similar results were
obtained when subgroup analyses were performed using
the 14 studies of full dose pegIFN and ribavirin for
48 weeks vs. the 7 with other treatment regimens (OR
5.20 vs. 3.94, p = 0.25), the 14 high quality vs. 7 low
quality studies (OR 5.05, vs. 3.93, P = 0.23) and the 10
studies of only treatment naïve vs. the 11 studies of both
treatment naïve and treatment experienced patients (OR:
4.74 vs. 4.65, P = 0.85) (supplementary Table S1). There
was no evidence of publication bias based on the Har-
bord and Peters tests (P = 0.29 and P = 0.48 respec-
tively).
DISCUSSION
This meta-analysis clearly demonstrates that the preva-
lence of the favourable IL-28B polymorphism (CC) is
signiﬁcantly inﬂuenced by subject race (Figure 2). In
addition, a consistent and signiﬁcantly higher SVR rate
was noted in all of the patient groups analysed among
the patients with the favourable IL-28B genotype (Fig-
ure 3). These observations indicate that the IL-28B
region plays a fundamental role in the response of all
HCV genotype 1 patients to interferon-based therapy. In
addition, the similar OR of the favourable IL-28B geno-
type in predicting SVR in the HIV co-infected Caucasian
Caucasian HIV(–)
Asian African-American
Caucasian HIV(+)
(n = 3110) (n = 263)
(n = 2612) (n = 452)
41% 46%
13%
73%
Favourable IL-28B genotype
Unfavourable IL-28B genotype
Figure 2 | Distribution of the favourable IL-28B
genotype by ethnic group. The prevalence of the
favourable IL-28B (rs12979860 CC or rs8099917 TT)
was signiﬁcantly higher in Caucasian vs. African-
American patients (41% vs. 13%, P < 0.001) and in
Asians vs. Caucasian (73% vs. 41%, P < 0.001)
patients without HIV co-infection. In contrast, the
prevalence was similar in the Caucasian HCV patients
with and without HIV co-infection (46% vs. 41%,
P = 0.13).
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Asian HCV genotype 1
Overall
Tanaka
Hayes
Huang
Lin
Kurosaki
Sinn
Hayashi
Akuta
Author
5.66 (3.99, 8.02)
12.09 (6.54, 22.36)
3.53 (2.50, 5.00)
5.32 (2.44, 11.58)
4.25 (1.66, 10.92)
6.51 (3.89, 10.91)
2.58 (0.60, 11.04)
8.66 (4.34, 17.27)
4.89 (2.60, 9.20)
OR (95% CI)
1105/1901
125/196
311/588
121/187
123/170
172/345
31/46
127/219
95/150
SVR in CC
141/711
15/118
54/224
10/39
8/21
21/151
4/9
11/80
18/69
SVR in CT/TT
Overall
Stattermayer
Lindh
Suppiah
Bochud
Fattovich
Alestig
Darling
Montes-Cano
Thompson
3.88 (2.75, 5.49)
4.97 (3.03, 8.14)
3.98 (1.60, 9.91)
2.28 (1.73, 3.01)
2.06 (1.01, 4.21)
8.17 (3.22, 20.70)
11.69 (2.29, 59.71)
5.72 (1.97, 16.60)
2.79 (1.44, 5.39)
4.77 (3.70, 6.16)
843/1266
102/129
30/38
247/442
29/44
35/42
16/18
49/54
34/63
301/436
686/1844
105/243
33/68
145/406
61/126
30/79
13/32
36/57
29/98
234/735
Overall
McCarthy
Darling
Thompson
4.63 (2.52, 8.50)
1.46 (0.14, 15.10)
3.62 (0.85, 15.48)
5.43 (2.70, 10.92)
27/59
1/8
6/9
20/42
73/393
4/45
32/90
37/258
1.1 .5 3 5
Caucasian HCV genotype 1
African-American HCV genotype 1
929/30914.68 (3.75, 5.83) 2040/3346POOLED OVERALL  
*D&L random effects method
(a)
(b)
(c)
Figure 3 | Forest plots of the IL-28B genotype and SVR in HCV genotype 1 patients of varying race without HIV
co-infection. (a) Asian HCV genotype 1, (b) Caucasian HCV genotype 1 and (c) African-American HCV genotype 1.
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patients when compared with the HIV () Caucasian
patients (5.49 vs. 3.88, P = 0.36) (Figures 3 and 4) indi-
cates that this factor is equally important in immunosup-
pressed individuals who generally have a lower
likelihood of SVR due to higher baseline levels of HCV
RNA and more severe liver disease.37–39
The SVR rate with a 48-week course of pegIFN and
ribavirin treatment has traditionally been highest in
Asian populations, lowest in African-Americans and
intermediate in Caucasians.6, 40 In our analysis, the
pooled SVR rates were substantially lower in African-
Americans (22%) as compared with the other two
groups, but similar in Asians (48%) and Caucasians
(49%). We noted a particularly lower than expected
pooled SVR in the Asian IL-28B favourable patients
(58%) compared with the unfavourable Asian IL-28B
genotypes (20%) (Table 1). This ﬁnding may, in part, be
related to the inclusion of Asian patients who had previ-
ously failed pegIFN and ribavirin therapy in up to six of
the studies. Although we were unable to determine the
exact proportion of previously treated patients, one
would anticipate that this may be a biased population
towards general nonresponders who may have a lower
than expected response to treatment as was noted in our
subgroup analysis of Caucasian patients. In addition, the
use of shorter durations of combination therapy in three
of the Asian studies, lower doses of ribavirin in ﬁve of
the studies and a higher overall proportion of patients
with advanced liver ﬁbrosis may have played a role
(Table 1).
Multivariate regression analyses conducted in several
of the individual studies conﬁrmed that IL-28B genotype
remains a signiﬁcant pre-treatment predictor of SVR
even after controlling for other well-known host and
viral factors.11, 17, 21, 25–27, 29, 31, 33–36 However, because
these data were not provided in an analysable format, we
were unable to combine the IL-28B data with other clini-
cal variables to develop a robust mathematical model
from the pooled results. How to use IL-28B data with
other pre-treatment predictors to accurately estimate an
individual patient’s chance of response to therapy
remains a clinically important, but unresolved issue.41–44
The data from the current meta-analysis suggest that the
impact of IL-28B appears to be similar in all of the
patient subgroups analysed and was not greatly inﬂu-
enced by duration of therapy or other study characteris-
tics, except in Caucasian mono-infected patients.
Nonetheless, additional large prospective studies involv-
ing the full spectrum of HCV patients that are likely to
be encountered in clinical practice, including patients of
Hispanic ethnicity, are needed to provide more robust
models for clinicians to use.
The choice of which IL-28B SNP to use in testing var-
ies by patient race. A recent retrospective database study
demonstrated that while there is a high concordance
between rs12979860 and rs8099917 in Asians, the rate of
concordance is substantially lower in non-Asian popula-
tions.13 Several of the Asian studies included in this
meta-analysis conﬁrmed this ﬁnding by genotyping
patients at both SNPs.26, 29, 30 In contrast, it appears that
Caucasian HIV(+), HCV genotype 1
Overall
Pineda
Author
Rallon
Aparicio
5.49 (3.02, 9.96)
5.00 (1.81, 13.78)
OR (95% CI)
4.38 (1.79, 10.70)
10.33 (2.81, 38.06)
65/120
17/34
22/34
26/52
29/143
8/48
18/61
3/34
1.1 .5 3 5
SVR in CC SVR in CT/TT
*D&L random effects method
Figure 4 | Forest plot of the IL-28B genotype and SVR in Caucasian HCV genotype 1 patients with HIV co-infection.
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a larger proportion of patients are classiﬁed as the
favourable IL-28B genotype when the rs8099917 SNP is
utilised in Caucasian studies.19, 20, 24 Therefore, use of
the rs8099917 SNP in non-Asian populations may lead
to misclassiﬁcation of IL-28B genotype and reduce the
ability to accurately predict SVR.
The role of IL-28B genotyping also needs to be better
deﬁned in the era of DAAs, such as telaprevir and boce-
previr. The DAAs in combination with pegIFN and riba-
virin are associated with signiﬁcantly higher SVR rates in
genotype 1 patients compared with dual therapy. How-
ever, the role of IL-28B genotyping in DAA treated
patients remains unclear as uniform testing for this
parameter was not conducted in the phase 3 multicenter
licensing trials. Nonetheless, IL-28B genotype has been
shown to be a predictor of SVR in smaller subgroups of
patients undergoing triple therapy with a DAA, PegIFN
and ribavirin.45, 46 However, triple therapy is also associ-
ated with greater costs and more side effects including
rash and anaemia, and current regimens using DAAs
may increase the risk of developing viral resistance. Fur-
thermore, a recent analysis demonstrated that triple ther-
apy is not cost-effective in subjects with an IL-28B CC
genotype due to their excellent response to dual ther-
apy.47 Therefore, our pooled data of the strength of asso-
ciation between IL-28B genotype and SVR in different
patient populations receiving only pegIFN and ribavirin
may prove important to regulatory agencies, clinicians,
patients and third party payers.
Despite their increased potency, DAAs are not currently
approved in many important subgroups including HCV
patients with genotype 2/3 infection and all HIV co-
infected patients. In HIV co-infected patients, there is a
particular concern for drug-drug interactions between the
available protease inhibitors and several of the commonly
used antiretroviral agents. Therefore, IL-28B testing may
play a particularly important role in HIV/HCV co-infected
patients contemplating pegIFN and ribavirin therapy until
additional DAAs are developed and tested. Recent data
suggest that IL-28B genotyping in conjunction with base-
line HCV viral load may help identify HIV co-infected
patients who are likely to achieve SVR.48, 49
A limitation of the current study includes our inability
to directly compare the role of IL-28B genotyping to other
host, viral and therapeutic factors in a multivariate man-
ner. Therefore, additional studies that incorporate multiple
pre-treatment predictors with genetic data in a large
cohort of prospectively treated patients who are given the
same treatment regimen are needed. Nonetheless, robust
and consistent associations of IL-28B genotype and SVR
were shown in all of the groups analysed (Figures 3& 4).
In addition, our results support recent reports of low con-
cordance between the two major IL-28B SNPs in some
Caucasian populations.13 For this meta-analysis of a pre-
dictive genetic test, we had to create our own study quality
assessment scale which has not been independently vali-
dated. Furthermore, studies of the IL-28B polymorphisms
in the African-American population remain limited
(Table 1). Nonetheless, the current meta-analysis repre-
sents the largest pooling of IL-28B genotype data in peg-
IFN and ribavirin treated patients to date. Lastly, all of the
studies of HIV co-infected patients were from Spain, and
whether the results will be generalisable to other HIV co-
infected patients treated in other countries requires further
study.
In conclusion, the current meta-analysis shows that
the favourable IL-28B genotype is associated with a sig-
niﬁcantly higher SVR rate in HCV genotype 1 patients
treated with pegIFN and ribavirin. Furthermore, this
ﬁnding is consistent across different racial groups who
have varying distributions of the IL-28B polymorphism
as well as in Caucasian HCV patients with HIV co-infec-
tion. IL-28B genotype was also signiﬁcantly associated
with the likelihood of achieving RVR in a limited num-
ber of studies. Although further studies are needed to
develop a more comprehensive predictive model of SVR,
IL-28B genotyping will likely play an important role in
guiding treatment decisions for HCV genotype 1 patients
seeking pegIFN and ribavirin based therapy.
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